Mer­ck gets a patent win for mus­cle re­lax­ant re­ver­sal drug

Mer­ck won a patent law­suit that al­lows it to keep mar­ket­ing a block­buster surgery drug un­til ear­ly 2026.

The phar­ma com­pa­ny said Tues­day that the US Dis­trict Court for the Dis­trict of New Jer­sey ruled in its fa­vor, say­ing Mer­ck had cor­rect­ly cal­cu­lat­ed the pe­ri­od of a Patent Term Ex­ten­sion, a reg­u­la­to­ry tool that can be used to re­store some patent time lost dur­ing reg­u­la­to­ry re­view of a new drug.

“We look for­ward to con­tin­u­ing to pro­vide Brid­ion to pa­tients who need it,” a Mer­ck spokesper­son said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER